BridgeBio Oncology Therapeutics, Inc. - BBOT
Insiders (Form 4) · last 180 days · showing up to 200 transactions
· Form 144 is shown in the SEC filings tab
· Updating…
Visible: 0
Transaction codes:
P = Open-market purchase ·
S = Open-market sale ·
A = Grant/award ·
M = Exercise/conversion of derivative ·
G = Gift ·
F = Tax withholding ·
J = Other ·
A/D:
A = Acquired (buy/receive) ·
D = Disposed (sell/give)
| Filed | Owner | Title | Code | A/D | Shares | Price | Value | Shares after | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jul 06, 2026 | Chief Med & Dev Officer | F | D | 1,047.0 | 7.8 | 8,166.6 | 44,576.0 | View | |
| Jul 06, 2026 | Principal Accounting Officer | F | D | 125.0 | 7.8 | 975.0 | 5,306.0 | View | |
| Jul 06, 2026 | COO & Principal Financial Ofcr | F | D | 343.0 | 7.8 | 2,675.4 | 14,495.0 | View | |
| Jul 06, 2026 | President and CEO | F | D | 1,047.0 | 7.8 | 8,166.6 | 44,576.0 | View | |
| Jul 06, 2026 | — | J | A | 130,865.0 | 0.0 | 0.0 | 6,083,221.0 | View | |
| Jul 06, 2026 | — | J | A | 1,704,862.0 | 0.0 | 0.0 | 5,010,332.0 | View | |
| Jul 06, 2026 | — | J | A | 2,692,459.0 | 0.0 | 0.0 | 4,879,995.0 | View | |
| Jul 06, 2026 | — | J | D | 4,528,186.0 | 0.0 | 0.0 | 0.0 | View | |
| Jun 18, 2026 | — | A | A | 31,675.0 | 0.0 | 0.0 | 31,675.0 | View | |
| Jun 18, 2026 | — | A | A | 31,675.0 | 0.0 | 0.0 | 31,675.0 | View | |
| Jun 18, 2026 | — | A | A | 7,289.0 | 0.0 | 0.0 | 7,289.0 | View | |
| Jun 18, 2026 | — | A | A | 31,675.0 | 0.0 | 0.0 | 31,675.0 | View | |
| Jun 18, 2026 | — | A | A | 31,675.0 | 0.0 | 0.0 | 31,675.0 | View | |
| Jun 18, 2026 | — | A | A | 31,675.0 | 0.0 | 0.0 | 31,675.0 | View | |
| Jun 18, 2026 | — | A | A | 31,675.0 | 0.0 | 0.0 | 31,675.0 | View | |
| May 12, 2026 | COO & Principal Financial Ofcr | A | A | 758,222.0 | 0.0 | 0.0 | 758,222.0 | View | |
| May 12, 2026 | President and CEO | A | A | 1,103,837.0 | 0.0 | 0.0 | 1,103,837.0 | View | |
| May 05, 2026 | Chief Med & Dev Officer | F | D | 1,047.0 | 9.03 | 9,454.41 | 45,623.0 | View | |
| May 05, 2026 | President and CEO | F | D | 1,047.0 | 9.03 | 9,454.41 | 45,623.0 | View | |
| May 05, 2026 | — | F | D | 524.0 | 9.03 | 4,731.72 | 22,806.0 | View | |
| Mar 26, 2026 | — | A | A | 63,350.0 | 0.0 | 0.0 | 63,350.0 | View | |
| Mar 12, 2026 | Chief Med & Dev Officer | A | A | 210,000.0 | 0.0 | 0.0 | 210,000.0 | View | |
| Mar 12, 2026 | Chief Med & Dev Officer | A | A | 46,670.0 | 0.0 | 0.0 | 46,670.0 | View | |
| Mar 12, 2026 | Chief Scientific Officer | A | A | 210,000.0 | 0.0 | 0.0 | 210,000.0 | View | |
| Mar 12, 2026 | Chief Scientific Officer | A | A | 46,670.0 | 0.0 | 0.0 | 46,670.0 | View | |
| Mar 12, 2026 | Chief Financial Officer | A | A | 105,000.0 | 0.0 | 0.0 | 105,000.0 | View | |
| Mar 12, 2026 | Chief Financial Officer | A | A | 23,330.0 | 0.0 | 0.0 | 23,330.0 | View |